Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic option for cancer patients in recent years. Despite its success, this approach faces acknowledged limitations and potential toxicities, such as antigen escape, on-target off-tumor effects, and an immunosuppressive microenvironment. To address the challenges associated with conventional CAR-T therapy, researchers are exploring innovative CAR strategies. These include the expression of dual or tandem CARs, the remodulation of CAR structure, and combination immunotherapies with checkpoint blockade. An alternative approach involves utilizing immune cell types such as natural killer (NK) cells in CAR-based therapies. CAR-NK cell therapies, created using the same receptor-antigen hybrid technology as CAR-T, express the CAR in NK cells. Compared to CAR-T therapy, CAR-NK cell therapy is considered safer with a reduced risk of negative immune side effects. Clinical trials have demonstrated promising results for CAR-NK cell therapies in both solid tumors and hematological malignancies. In this context, the session will emphasize how Sino Biological is at the forefront of facilitating the development of CAR-T and CAR-NK cell therapies through comprehensive solutions. These solutions encompass every stage, from CAR development to the preparation of CAR-T and CAR-NK cells, along with CAR-T/ CAR-NK cells quality control.

Learning Objectives: 

1. Summarize the different CAR-associated cellular immunotherapies in clinic.

2. Review current limitations and potential strategies of CAR-associated cellular immunotherapy.

3.Discuss Sino Biological solutions supporting CAR-T therapy, CAR-NK cell therapy development.